For research use only. Not for therapeutic Use.
Vesencumab（Cat No.:I042211）is a monoclonal antibody designed to target the protein CLEC-14A (C-type lectin domain family 14 member A), which is involved in the development of blood vessels in tumors, a process known as angiogenesis. By binding to CLEC-14A, vesencumab aims to inhibit tumor blood vessel formation, thereby starving tumors of the nutrients and oxygen they need to grow. It is being studied in clinical trials for its potential to treat solid tumors, including non-small cell lung cancer (NSCLC), with the goal of improving patient outcomes by targeting tumor vasculature.
| Catalog Number | I042211 |
| CAS Number | 1205533-60-3 |
| Purity | ≥95% |
